União Europeia - inglês - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs.onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

União Europeia - inglês - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs.onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components.the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

União Europeia - inglês - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

União Europeia - inglês - EMA (European Medicines Agency)

ceva santé animale - inactivated influenza-a virus / swine - immunologicals - pigs - active immunisation of pigs from the age of 56 days onwards, including pregnant sows, against swine influenza caused by subtypes h1n1, h3n2 and h1n2 to reduce clinical signs and viral lung load after infection.onset of immunity: 7 days after primary vaccinationduration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity, which provides clinical protection of piglets for at least 33 days after birth.

União Europeia - inglês - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer / recombinant type-d pasteurella-multocida toxin (pmtr) - immunologicals - pigs (gilts and sows) - for the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with bordetella-bronchiseptica and pasteurella-multocida infections during the fattening period. challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

União Europeia - inglês - EMA (European Medicines Agency)

zoetis belgium sa - live attenuated aujeszky's disease virus - immunologicals - pigs - active immunisation of pigs from the age of 10 weeks to prevent the mortality and clinical signs of aujeszky's disease and to reduce the excretion of aujeszky's disease field virus. passive immunisation of the progeny of vaccinated gilts and sows to reduce mortality and clinical signs of aujeszky's disease and to reduce the excretion of aujeszky's disease field virus.

União Europeia - inglês - EMA (European Medicines Agency)

zoetis belgium s.a. - leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090, l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091 (all inactivated) - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia), immunologicals for canidae - dogs - active immunisation of dogs from six weeks of age to prevent clinical signs, infection and urinary excretion caused by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. onset of immunity: immunity has been demonstrated from 4 weeks after completion of the primary course. duration of immunity: at least one year following the primary vaccination course.

União Europeia - inglês - EMA (European Medicines Agency)

zoetis belgium sa. - canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090 and l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091 (all inactivated) - immunologicals for canidae, live viral and inactivated bacterial vaccines - dogs - active immunisation of dogs from six weeks of age. - to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus, - to prevent clinical signs, infection and urinary excretion caused by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. onset of immunity: immunity has been demonstrated from 3 weeks after completion of the primary course for cpiv and from 4 weeks after completion of the primary course for leptospira components. duration of immunity: at least one year following the primary vaccination course for all components of versican plus pi/l4.

União Europeia - inglês - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1 - immunologicals - cattle - active immunisation of cattle from 2½ months of age for the prevention of viraemia caused by bluetongue virus, serotype 1.onset of immunity: 15 days after completion of the primary vaccination course.duration of immunity: 12 months.

União Europeia - inglês - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype-1 - immunologicals - sheep - active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.onset of immunity: 21 days after completion of the primary vaccination scheme.duration of immunity: 12 months.